Nasdaq Biotechnology Ishares ETF (IBB)

$141.30 +1.07 (0.76%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 552,023
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Phone: 1-800-474-2737
Honeystocks
Honeystocks Mar. 21 at 12:34 AM
$IBB - Biotech's stopped going up exactly where they were supposed to stop going up. I know technical analysis gets a bad rap, but I'd rather use price levels than listen to someone's hot take on the sector fundamentals and their 10yr time horizon.
1 · Reply
Diefreeandsell
Diefreeandsell Mar. 20 at 1:09 PM
$IBRX $IBB $QQQ $TECL $SOXL The analyst community hasn't modeled THE NCCN ADD yet but our own analyst has! The addition strongly supports a higher revenue forecast, analysts typically wait for a management "catalyst event" to confirm the commercial rollout strategy before officially raising price targets. 38th Annual ROTH Conference (March 22–24, 2026) This event focuses on 1-on-1 meetings and analyst-moderated fireside chats. Expectation: CEO Richard Adcock is expected to discuss the NCCN inclusion and the March 9 resubmission of the supplemental BLA (sBLA) for papillary disease. Analyst updates often follow these private and public management sessions. NCCN 2026 Annual Conference (March 27–29, 2026) Why it matters: As the first major clinical gathering since the bladder cancer guideline update, expert panels will discuss the practical integration of ANKTIVA plus BCG for papillary-only patients. https://immunitybio.com/38th-annual-roth-conference/
1 · Reply
QuantLake
QuantLake Mar. 20 at 6:18 AM
Gold Miners tumbled 5.91% Thursday Alt Asset ETFs Breakdown: Top 2 (by %): $ICLN +2.07%, $IBB +0.42% Bottom 2: $GDX -5.91%, $IBIT -1.09% Quantlake Read (Intermediate-Term): $ICLN Clean Energy: Bullish Momentum - Neutral Sentiment. $IBB Biotechnology: Bullish Momentum - Neutral Sentiment. $IBIT Bitcoin Trust: Bearish Momentum - Negative Sentiment. $GDX Gold Miners: Bullish Momentum - Positive Sentiment.
0 · Reply
pnvoss
pnvoss Mar. 19 at 4:19 AM
$IBB biotech and pharma will selloff as oil sells off. $SPY Money will flow into consumer stocks and tech. Crypto and airliner and cruise liner stocks. Opinion Get out of safe haven stocks as oil starts to crash from highs. Opinion
0 · Reply
Diefreeandsell
Diefreeandsell Mar. 18 at 5:39 PM
$IBRX $XBI $IBB $TNA $SOXL so tutes are buying and hiding purchase under xbi mechanical selling, smart. Now that the "forced selling" from the ETF rebalance is thinning out, the true buying pressure is hitting the tape. As one user noted, IBRX is up over 5% today even as the broader markets and futures are red. According to recent data, short interest in IBRX remains incredibly high—around 42% of the float. Shorts were likely counting on the ETF rebalancing to keep the price down and will soon be trapped. With the NCCN "Holy Grail" update now official, any move toward $9.00 could force those shorts to cover, especially since the NCCN add is not yet baked into many analyst projections, hence a squeeze, maybe epic in proportion. You all still watching for a pullback?😂🤣😜
0 · Reply
Diefreeandsell
Diefreeandsell Mar. 18 at 5:31 PM
$IBRX we have decoupled from $XBI prob got picked up by $IBB now that we too big a pct for xbi, it sells winners to buy losers. Selling is already done. Now the real reason the stock is reacting today and why it might "blow through" those conservative estimates is they r starting to price in exceeding of those $195M estimates that were pre NCC add(Unexpected this early by some). Institutional "De-risking" Analysts are notoriously cautious. The $195M projection for 2026 represents a ~73% increase over the $113M earned in 2025 2025 Beat: They already beat estimates in Q4 2025, pulling in $38.3M vs the $35.9M expected. High Targets: Analysts with "Strong Buy" ratings, like those at D. Boral Capital(love that GUY), have price targets as high as $23.00, which implies they expect revenue to dwarf that $195M consensus, someone did their homework! The Verdict: That $195M is the "safe" number for the math nerds. The actual number will be much higher now that the NCCN has opened the floodgates. -->$9->
0 · Reply
Diefreeandsell
Diefreeandsell Mar. 18 at 4:44 PM
$IBRX $XBI $IWM $IBB $SOXL LOOKS LIKE XBI finsihed rebal early! On a red day like this it's great to be in IBRX! BUY THE DIPS! TuTes are and have been while dummies take shitty profits! NCCN add is the holy grail till more FDA approvals hit!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 18 at 11:03 AM
$IBB RSI: 36.52, MACD: -1.6071 Vol: 3.53, MA20: 171.58, MA50: 172.39 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
todn
todn Mar. 18 at 12:46 AM
$IBB $IBRX $IWM $SOXL $XBI makes sense
0 · Reply
GlassIsHalfEmpty
GlassIsHalfEmpty Mar. 17 at 11:59 PM
$IBB $IBRX $IWM $SOXL $XBI this person 🧍 got it right! No atm , just shorts and xbi mechanical selling. Ends soon , listen to best advice you’ll get here today!👊🚀
0 · Reply
Latest News on IBB
Revenge Of The Dividend Stocks

Feb 7, 2026, 8:15 AM EST - 6 weeks ago

Revenge Of The Dividend Stocks

AAPL AMH AMT ARKK CDL CGDG CHAT

IBB: Beyond The 2025 Surge, Biotech Breakout

Jan 27, 2026, 5:10 AM EST - 7 weeks ago

IBB: Beyond The 2025 Surge, Biotech Breakout

IBB: Biotech's Hot Streak May Cool

Jan 26, 2026, 6:22 AM EST - 7 weeks ago

IBB: Biotech's Hot Streak May Cool

Nvidia–Eli Lilly Tie-Up Shows Why AI Drug Discovery Is The Next ETF Battleground

Jan 14, 2026, 12:23 PM EST - 2 months ago

Nvidia–Eli Lilly Tie-Up Shows Why AI Drug Discovery Is The Next ETF Battleground

BOTZ CHAT SMH SOXX WTAI

Funding for Risky Biotechs Is Returning

Jan 12, 2026, 12:00 PM EST - 2 months ago

Funding for Risky Biotechs Is Returning

XBI

Pharma stocks are set to take off this year, says UBS' Michael Yee

Jan 8, 2026, 11:01 AM EST - 2 months ago

Pharma stocks are set to take off this year, says UBS' Michael Yee

LLY VTYX

Mizuho's Jared Holz on what biotech dealmaking looks like in 2026

Dec 31, 2025, 2:27 PM EST - 2 months ago

Mizuho's Jared Holz on what biotech dealmaking looks like in 2026

XBI

Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus

Dec 23, 2025, 2:04 PM EST - 3 months ago

Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus

NVO PPH VHT XBI

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

Dec 19, 2025, 6:25 PM EST - 3 months ago

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

ALNY AMGN ARGX AZN

3 Potential Mid-Cap Biotech Buyout Targets In 2026

Dec 3, 2025, 6:22 PM EST - 3 months ago

3 Potential Mid-Cap Biotech Buyout Targets In 2026

COGT TVTX XBI CYTK

iShares Biotechnology ETF: The M&A Wave Behind The Suddenly Booming Biotech Sector

Nov 17, 2025, 9:44 AM EST - 4 months ago

iShares Biotechnology ETF: The M&A Wave Behind The Suddenly Booming Biotech Sector

If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz

Nov 14, 2025, 6:17 PM EST - 4 months ago

If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz

CDTX MRK XBI XLV

'Fast Money' traders talk how to play biopharma space

Nov 11, 2025, 6:56 PM EST - 4 months ago

'Fast Money' traders talk how to play biopharma space

XLV

Biotech is back and a constructive place to put money to work, says Piper Sandler's Craig Johnson

Nov 11, 2025, 3:07 PM EST - 4 months ago

Biotech is back and a constructive place to put money to work, says Piper Sandler's Craig Johnson

XBI

Investing In Health Stocks - How Policy Clarity Is Opening Doors

Nov 11, 2025, 10:13 AM EST - 4 months ago

Investing In Health Stocks - How Policy Clarity Is Opening Doors

AGNG ARKG BBC BBH BBP BIB BIS

Trade Tracker: Jason Snipe buys the IBB

Oct 17, 2025, 1:30 PM EDT - 5 months ago

Trade Tracker: Jason Snipe buys the IBB

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 5 months ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB BMY

‘Fast Money' traders talk opportunities in health care stocks

Oct 1, 2025, 5:48 PM EDT - 6 months ago

‘Fast Money' traders talk opportunities in health care stocks

AMGN BIIB BMY LLY MRK MRNA PFE

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz

Sep 9, 2025, 10:41 AM EDT - 6 months ago

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz

XBI

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Sep 3, 2025, 3:32 PM EDT - 7 months ago

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

ARGX BBH BMRN CYTK XBI

BBH Vs. IBB: How To Prepare For The Next Biotech Growth Cycle With BBH

Sep 1, 2025, 8:03 AM EDT - 7 months ago

BBH Vs. IBB: How To Prepare For The Next Biotech Growth Cycle With BBH

Trump's deadline looms for Big Pharma companies facing new tariffs

Jul 16, 2025, 3:30 PM EDT - 8 months ago

Trump's deadline looms for Big Pharma companies facing new tariffs

XLV

Heard on the Street: Why pharma stocks have outperformed the broader market since Trump threatened the industry with a 200% tariff

Jul 13, 2025, 7:01 AM EDT - 8 months ago

Heard on the Street: Why pharma stocks have outperformed the broader market since Trump threatened the industry with a 200% tariff

XLV

Trump threatens 50% tariffs on copper, 200% on pharmaceuticals

Jul 9, 2025, 11:09 AM EDT - 9 months ago

Trump threatens 50% tariffs on copper, 200% on pharmaceuticals

CPER XBI

Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI

Jul 6, 2025, 11:12 AM EDT - 9 months ago

Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI

XBI

5 Stocks I'm Buying As The 'Big Beautiful Bill' Pushes The Market To New Highs

Jul 5, 2025, 8:05 AM EDT - 9 months ago

5 Stocks I'm Buying As The 'Big Beautiful Bill' Pushes The Market To New Highs

ACHC AMH ARE CHAT COLD ELS FSLR

Fast Money: WTI, IBB, UBER, CAT

Jun 13, 2025, 6:20 PM EDT - 10 months ago

Fast Money: WTI, IBB, UBER, CAT

UBER CAT

Healthcare Sector Checkup As U.S. Looks To Change Regulations

May 30, 2025, 3:30 PM EDT - 10 months ago

Healthcare Sector Checkup As U.S. Looks To Change Regulations

AGNG ARKG BBC BBH BBP BIB BIS

IBB: Now Is The Time To Be Contrarian

May 29, 2025, 10:59 AM EDT - 10 months ago

IBB: Now Is The Time To Be Contrarian

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

May 28, 2025, 12:22 PM EDT - 10 months ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN BIIB DHR GILD ILMN NVS SDGR

Trump is right about drug prices. He's just going about it all wrong.

May 13, 2025, 1:43 PM EDT - 11 months ago

Trump is right about drug prices. He's just going about it all wrong.

XBI XLV

New vaccine chief rocks pharmaceutical stocks

May 7, 2025, 11:13 AM EDT - 11 months ago

New vaccine chief rocks pharmaceutical stocks

BNTX MRNA NVAX PFE GSK SRPT XBI

Trump Says Pharmaceutical Tariffs Coming in Near Future

Apr 14, 2025, 2:03 PM EDT - 1 year ago

Trump Says Pharmaceutical Tariffs Coming in Near Future

ABBV AMGN AZN BMY GSK JNJ LLY

Sell into strength in pharma, says Mizuho's Jared Holz

Apr 11, 2025, 7:17 PM EDT - 1 year ago

Sell into strength in pharma, says Mizuho's Jared Holz

XBI

Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages

Apr 11, 2025, 10:30 AM EDT - 1 year ago

Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages

ABBV AMGN AZN BMY GSK JNJ LLY

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

Apr 11, 2025, 5:30 AM EDT - 1 year ago

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

XBI

BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks

Apr 9, 2025, 6:32 PM EDT - 1 year ago

BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks

ABBV AMGN AZN BMY GSK JNJ LLY

Explainer: Prescription drugs become a target in Trump's trade war

Apr 9, 2025, 2:27 PM EDT - 1 year ago

Explainer: Prescription drugs become a target in Trump's trade war

ABBV AMGN AZN BMY GSK JNJ LLY

Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'

Apr 9, 2025, 1:06 PM EDT - 1 year ago

Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'

ABBV AMGN AZN BMY GSK JNJ LLY

Why drug stocks are no longer a safe haven from the stock market's turmoil

Apr 9, 2025, 11:49 AM EDT - 1 year ago

Why drug stocks are no longer a safe haven from the stock market's turmoil

ABBV AMGN BMY JNJ LLY MRK PFE

Invest In A New Biotech Bull Market With XBI And IBB

Mar 2, 2025, 8:33 AM EST - 1 year ago

Invest In A New Biotech Bull Market With XBI And IBB

XBI

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Feb 25, 2025, 11:06 AM EST - 1 year ago

Seeking Stocks With Vitality In The Volatile Healthcare Sector

XLV AGNG ARKG BBC BBH BBP BIB

How tariffs could impact pharma and early-stage healthcare investments

Feb 3, 2025, 6:43 PM EST - 1 year ago

How tariffs could impact pharma and early-stage healthcare investments

XLV

Biotech walks a 'tightrope' amid unclear funding, regulations

Jan 30, 2025, 7:06 PM EST - 1 year ago

Biotech walks a 'tightrope' amid unclear funding, regulations

DCTH ELVN

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

Jan 13, 2025, 6:10 PM EST - 1 year ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

iShares Biotechnology ETF: Playing Defense

Dec 10, 2024, 1:33 PM EST - 1 year ago

iShares Biotechnology ETF: Playing Defense

Mizuho's Jared Holz on what Trump's FDA pick means for biotech innovation

Nov 25, 2024, 6:44 PM EST - 1 year ago

Mizuho's Jared Holz on what Trump's FDA pick means for biotech innovation

HIMS LLY MRNA NVO PFE

Health care stocks jump on Trump's nominee for FDA head

Nov 25, 2024, 6:22 PM EST - 1 year ago

Health care stocks jump on Trump's nominee for FDA head

HIMS LFMD MRNA PFE

Final Trade: Euro, IBB, SMH, NEM

Nov 20, 2024, 6:21 PM EST - 1 year ago

Final Trade: Euro, IBB, SMH, NEM

SMH NEM

Honeystocks
Honeystocks Mar. 21 at 12:34 AM
$IBB - Biotech's stopped going up exactly where they were supposed to stop going up. I know technical analysis gets a bad rap, but I'd rather use price levels than listen to someone's hot take on the sector fundamentals and their 10yr time horizon.
1 · Reply
Diefreeandsell
Diefreeandsell Mar. 20 at 1:09 PM
$IBRX $IBB $QQQ $TECL $SOXL The analyst community hasn't modeled THE NCCN ADD yet but our own analyst has! The addition strongly supports a higher revenue forecast, analysts typically wait for a management "catalyst event" to confirm the commercial rollout strategy before officially raising price targets. 38th Annual ROTH Conference (March 22–24, 2026) This event focuses on 1-on-1 meetings and analyst-moderated fireside chats. Expectation: CEO Richard Adcock is expected to discuss the NCCN inclusion and the March 9 resubmission of the supplemental BLA (sBLA) for papillary disease. Analyst updates often follow these private and public management sessions. NCCN 2026 Annual Conference (March 27–29, 2026) Why it matters: As the first major clinical gathering since the bladder cancer guideline update, expert panels will discuss the practical integration of ANKTIVA plus BCG for papillary-only patients. https://immunitybio.com/38th-annual-roth-conference/
1 · Reply
QuantLake
QuantLake Mar. 20 at 6:18 AM
Gold Miners tumbled 5.91% Thursday Alt Asset ETFs Breakdown: Top 2 (by %): $ICLN +2.07%, $IBB +0.42% Bottom 2: $GDX -5.91%, $IBIT -1.09% Quantlake Read (Intermediate-Term): $ICLN Clean Energy: Bullish Momentum - Neutral Sentiment. $IBB Biotechnology: Bullish Momentum - Neutral Sentiment. $IBIT Bitcoin Trust: Bearish Momentum - Negative Sentiment. $GDX Gold Miners: Bullish Momentum - Positive Sentiment.
0 · Reply
pnvoss
pnvoss Mar. 19 at 4:19 AM
$IBB biotech and pharma will selloff as oil sells off. $SPY Money will flow into consumer stocks and tech. Crypto and airliner and cruise liner stocks. Opinion Get out of safe haven stocks as oil starts to crash from highs. Opinion
0 · Reply
Diefreeandsell
Diefreeandsell Mar. 18 at 5:39 PM
$IBRX $XBI $IBB $TNA $SOXL so tutes are buying and hiding purchase under xbi mechanical selling, smart. Now that the "forced selling" from the ETF rebalance is thinning out, the true buying pressure is hitting the tape. As one user noted, IBRX is up over 5% today even as the broader markets and futures are red. According to recent data, short interest in IBRX remains incredibly high—around 42% of the float. Shorts were likely counting on the ETF rebalancing to keep the price down and will soon be trapped. With the NCCN "Holy Grail" update now official, any move toward $9.00 could force those shorts to cover, especially since the NCCN add is not yet baked into many analyst projections, hence a squeeze, maybe epic in proportion. You all still watching for a pullback?😂🤣😜
0 · Reply
Diefreeandsell
Diefreeandsell Mar. 18 at 5:31 PM
$IBRX we have decoupled from $XBI prob got picked up by $IBB now that we too big a pct for xbi, it sells winners to buy losers. Selling is already done. Now the real reason the stock is reacting today and why it might "blow through" those conservative estimates is they r starting to price in exceeding of those $195M estimates that were pre NCC add(Unexpected this early by some). Institutional "De-risking" Analysts are notoriously cautious. The $195M projection for 2026 represents a ~73% increase over the $113M earned in 2025 2025 Beat: They already beat estimates in Q4 2025, pulling in $38.3M vs the $35.9M expected. High Targets: Analysts with "Strong Buy" ratings, like those at D. Boral Capital(love that GUY), have price targets as high as $23.00, which implies they expect revenue to dwarf that $195M consensus, someone did their homework! The Verdict: That $195M is the "safe" number for the math nerds. The actual number will be much higher now that the NCCN has opened the floodgates. -->$9->
0 · Reply
Diefreeandsell
Diefreeandsell Mar. 18 at 4:44 PM
$IBRX $XBI $IWM $IBB $SOXL LOOKS LIKE XBI finsihed rebal early! On a red day like this it's great to be in IBRX! BUY THE DIPS! TuTes are and have been while dummies take shitty profits! NCCN add is the holy grail till more FDA approvals hit!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 18 at 11:03 AM
$IBB RSI: 36.52, MACD: -1.6071 Vol: 3.53, MA20: 171.58, MA50: 172.39 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
todn
todn Mar. 18 at 12:46 AM
$IBB $IBRX $IWM $SOXL $XBI makes sense
0 · Reply
GlassIsHalfEmpty
GlassIsHalfEmpty Mar. 17 at 11:59 PM
$IBB $IBRX $IWM $SOXL $XBI this person 🧍 got it right! No atm , just shorts and xbi mechanical selling. Ends soon , listen to best advice you’ll get here today!👊🚀
0 · Reply
Diefreeandsell
Diefreeandsell Mar. 17 at 7:53 PM
$IBRX $XBI $IWM $IBB $SOXL Do i not give you best advice in advance of key catalysts? Buy the damn dip! you’ll thank me! What Happens Next? Once the XBI rebalance window closes (after this Friday's close), that massive "forced seller" disappears. If the analyst upgrades and NCCN-driven prescription growth continue, the shorts will be trapped without the "ETF selling cover" to hide behind. This often leads to a "Delayed Reaction" rally where the stock finally moves toward those $15+ price targets once the technical "selling sludge" clears.
2 · Reply
Diefreeandsell
Diefreeandsell Mar. 17 at 6:36 PM
$ $IBRX $XBI $IWM $IBB $SOXL xbi trimming/rebalancing shares to get back to equal weight. But other tutes are scooping up shares! say goodbye to under $8.5 in 30 minutes. You had more than enough time to add like i did too! NCCN add doubles patient pool eligible for Anktiva! Renders Fda decision on pappliary only mute! Expect upgrades and higher pt by end of week. Opex will be epic!🥁🥁🥁
1 · Reply
haha1978
haha1978 Mar. 17 at 1:35 PM
$CPIX Not the Ifetroban. $XBI $IBB $QQQ https://finviz.com/news/337974/cumberland-pharmaceuticals-launches-new-sancuso-website-featuring-educational-resources-for-chemotherapy-induced-nausea-and-vomiting
1 · Reply
haha1978
haha1978 Mar. 17 at 1:28 PM
$CADL $XBI $IBB $QQQ $SQQQ
0 · Reply
Diefreeandsell
Diefreeandsell Mar. 17 at 10:51 AM
$IBRX $XBI $IBB $TNA $MRNA Happy Saint Patty day Patrick Soon-Shiong! March 17! I did say was happening and Nccn addition means no dilution ! Impact of the Papillary-Only Indication Market Expansion: The "papillary-only" (without CIS) population is significantly larger than the CIS population—representing roughly 70% of the 60,000 NMIBC patients diagnosed annually in the U.S.. NCCN-Driven Prescribing: CEO Richard Adcock has noted that physicians could begin prescribing Anktiva for papillary-only disease once included in NCCN guidelines, even while the formal FDA supplemental BLA is still under review. 2026 Forecasts: Some analysts project revenue to climb to approximately $195 million in 2026, driven by this label expansion and continued commercial execution
0 · Reply
OceanThunder7
OceanThunder7 Mar. 16 at 1:59 PM
$IVVD another 5x potential move with this one $SPY $IBB $XBI
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Mar. 15 at 5:21 PM
Attached is a graph that compares actual FY25 revenues & 5-year (FY26 - FY30) analyst consensus revenue estimates of $MIRM $TARS & $TVTX The raw data used to compile the graph is provided at the bottom right. Note analysts project TARS & TVTX to generate virtually identical revenues by year & cumulatively over the next 5 years as MIRM yet both trade at sharply lower market caps. Both TARS & TVTX also generated higher gross profit margins (by 7 & 13%) on FY25 revenues v MIRM. The objective of this post is to identify the disconnect in revenue multiples of TARS & TVTX. This is in no way to bash MIRM. MIRM just posted a very respectable Q425 beat. TVTX has a meaningful 4/13/26 inflection point via Filspari PDUFA for FSGS. There is evidence that suggests a 2nd PDUFA extension is possible. We're genuinely curious if there's any other data driven reason for the disconnect in multiples. This is not investment advice. There may be very good reason. $XBI $IBB
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Mar. 14 at 9:46 PM
Attached see $SNDX valuation, analyst revenue estimates & related multiples compared to $DAWN 's M&A exit valuation. If DAWN's market cap (post M&A announcement) is now 1.03X DAWN 5-year analyst consensus, would SNDX command a higher 5-year multiple than 1.03X in a hypothetical M&A exit (excluding cash/debt) because; 1. SNDX revenues generated higher gross profit margins than DAWN in FY2025 (SNDX 96% to DAWN 90%)? 2. SNDX revenues come from 2 FDA approved therapies compared to DAWN's 1 FDA approved therapy (in theory lowering risk to an acquirer)? 3. SNDX 2 products both appear to have longer patent lives (Niktimvo FY36, Revuforj 6/8/37) than DAWN's Ojemda (June 35)? We're only asking the question. This is not investment advice. $INCY $XBI $IBB
2 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Mar. 14 at 4:08 PM
$NBIX 10-year analyst consensus revenue estimates versus $ASND & $BBIO. Analysts forecast NBIX will generate considerably more revenues than both ASND & BBIO yet NBIX trades at meaningfully lower valuations than both. NBIX product sales generated higher gross profit margins than both in FY2025 as well The objective of this post is to identify the apparent disconnect in NBIX’s valuation using these 2 peers as comparables for valuation (sharing the math). This is in no way to put down nor bash ANSD or BBIO. Both appear great commercial-stage non-oncology focused bios. We understand there is a rumor ASND is a near-term M&A candidate. If drugs are worth some NPV and/or multiple of projected sales, and NBIX trades at meaningfully lower multiples of analyst projected sales then does that suggest NBIX’s risk v reward profile is as compelling as ASND & BBIO? We’d genuinely like to understand a data driven reason the apparent disconnect is warranted. This is not investment advice. $XBI $IBB
2 · Reply
Diefreeandsell
Diefreeandsell Mar. 13 at 7:54 PM
$IBRX $XBI $IBB $ARKK $TNA Pretty soon they'll all be Banking with the "World Bank of NK Cells". If ImmunityBio has excess capacity, they could act as a specialized CDMO for other biotechs. This would generate high-margin "service revenue" while their own drugs like ANKTIVA continue their market ramp. BTW NANT GLOBAL Blockchain coming Soon, Shiong Style!
0 · Reply
Diefreeandsell
Diefreeandsell Mar. 13 at 4:55 PM
$IBRX $XBI $IBB $QQQ $MRNA This "World Bank of NK Cells" is a huge deal. No supply shortage for global rollout and none of the analysts have any sales projections outside of USA in their Price targets. What about co acting as CDMO mrf for other BP co's usin 'GMP-IN_A_BOX' Leonardo ai mfr tech?
1 · Reply
GlassIsHalfEmpty
GlassIsHalfEmpty Mar. 13 at 3:42 PM
$IBRX $XBI $IBB $QQQ $FATE This has to be worth billions. Proprietary AI robotic driven mfr bioreactors!
2 · Reply